Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for ...
FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting ...
Vera Therapeutics stock rose on FDA acceptance of atacicept BLA for priority review in IgAN, a potential multi-billion dollar ...
KORU Medical filed a 510(k) to use FreedomEDGE for subcutaneous PHESGO delivery, expanding into oncology and simplifying ...
Zenas BioPharma (ZBIO) stock plunges as the company posts late-stage trial data for its lead asset, obexelimab, in ...
Vera Therapeutics received priority review from the FDA for its biologics license application for atacicept to treat adults ...
Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...
Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...
Vera Therapeutics, Inc. ('Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic ...
Investing.com -- Vera Therapeutics Inc (NASDAQ:VERA) stock rose 4.4% Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback